CIK 0001867096 · Large accelerated filer
Xeris Biopharma Holdings, Inc.
Sign in to watch- Ticker
- XERS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 871082097
- Phone
- 844-445-5704
- Business address
- 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Executive or director change
- 4 Planned sale See Remarks sold 16,667 shares at $5.99 ($99,859)
- 4 Planned sale Director sold 10,834 shares at $5.54 ($60,036)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Option exercise See Remarks acquired 48,898 shares (option exercise)
- 4 Option exercise See Remarks acquired 41,927 shares (option exercise)
- 4 Planned sale See Remarks sold 16,667 shares at an average $6.25 ($104,086)
- 144 Insider Sale of Securities
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Regulation FD disclosure
- 4 Shares withheld for taxes See Remarks gave up 29,300 shares (to pay taxes)
- 4 Shares withheld for taxes See Remarks gave up 340,505 shares (to pay taxes)
- 4 Shares withheld for taxes See Remarks gave up 126,062 shares (to pay taxes)
- 4 Shares withheld for taxes See Remarks gave up 205,534 shares (to pay taxes)
- 4 Grant or award See Remarks acquired 121,293 shares (grant or award)
Page 4 of 18 · 346 filings